Humanin is a small mitochondria-derived peptide being studied for its role in cellular protection, metabolic regulation, and age-related disease — though human evidence remains very limited.
What it does
Humanin is a peptide (a short chain of amino acids) encoded not in the cell's nucleus but in mitochondrial DNA — the genetic material inside the energy-producing organelles of your cells. This makes it unusual: most peptides the body produces come from nuclear genes. Circulating humanin levels decline with age, which has led researchers to investigate whether restoring those levels might slow certain aging-related processes NCT06105229.
At the cellular level, humanin appears to act as a cytoprotective signal — meaning it helps cells survive stress. It binds to receptors on the cell surface and activates survival pathways that reduce apoptosis (programmed cell death). It also interacts with insulin signaling pathways, which has drawn interest in metabolic conditions like type 2 diabetes and kidney disease NCT06105229. Some researchers have also looked at its presence in muscle tissue, relevant to conditions involving muscle deterioration NCT05506228.
More recently, interest has extended to exercise physiology and kidney disease. One registered trial is specifically examining humanin's behavior during high-intensity physical exercise in patients with chronic kidney disease — a population where mitochondrial function and cellular stress are both impaired NCT07438002.
What the evidence shows
Acute kidney injury (AKI) biomarker and potential therapeutic target Early-stage human research — one registered clinical trial, no published results yet
A registered clinical trial is measuring plasma humanin levels in patients with acute kidney injury to assess whether it has clinical diagnostic or prognostic value NCT06105229. The hypothesis is that humanin's cytoprotective properties may be relevant to kidney cell survival under ischemic or toxic stress. No results have been published from this trial. The rationale is mechanistically plausible, but there is no human efficacy data yet.
Muscle biology in cerebral palsy Observational study — muscle biopsy analysis, no therapeutic intervention
One registered trial is analyzing muscle biopsies from patients with cerebral palsy during orthopedic surgery, with humanin as one of several targets being measured NCT05506228. This is observational, not interventional — researchers are characterizing what's happening in affected muscle tissue, not administering humanin. It's early-stage science establishing whether humanin expression patterns differ in this population.
Exercise response in chronic kidney disease Registered trial, no published results
A trial is examining how high-intensity physical exercise affects humanin levels in patients with chronic kidney disease, both those on dialysis and those in conservative treatment NCT07438002. The interest is in whether exercise-induced mitochondrial stress changes humanin signaling in a clinically meaningful way. Again, no results are yet available.
How it's used
In studies and self-reported protocols, humanin has been explored via subcutaneous injection, though no standardized dosing has been established in published human trials. Doses used in animal research vary widely depending on the model and endpoint. The three registered human trials listed here are observational or biomarker-focused — none of them involve administering humanin as a therapeutic agent to participants. No prescribing information or validated clinical dosing protocol exists at this time.
Side effects and safety
In the limited human context available, mild side effects reported in self-reported protocols include fatigue, headache, and injection site reactions. No serious adverse events have been documented in published human research, largely because controlled human intervention trials haven't been completed. Humanin is considered potentially contraindicated in people with active malignancy — the same cytoprotective signaling that may help healthy cells survive stress could theoretically help cancer cells do the same. It is also flagged as contraindicated in pregnancy and in hormone-sensitive conditions. Long-term safety in humans is entirely unknown.
Bottom line
Humanin is a genuinely interesting mitochondria-derived peptide with a plausible cellular protection mechanism and declining levels with age — but human evidence is currently limited to observational and biomarker trials with no published results. Anyone considering it is working well ahead of the clinical science, in territory where risks and benefits are largely uncharacterized.